Skip to main content

A bioinformatics investigation into the pharmacological mechanisms of javanica oil emulsion injection in non-small cell lung cancer based on network pharmacology methodologies



Javanica oil emulsion injection (JOEI) is an effective therapeutic option for patients with non-small cell lung cancer (NSCLC), but its mechanisms have not been fully elucidated.


In this study, we utilized network pharmacology to systematically investigate the bioactive components and targets of JOEI, identify common targets in NSCLC, and understand and evaluate the underlying mechanism of JOEI in the treatment of NSCLC through expression level, correlation, enrichment, Cox, survival and molecular docking analyses. The results indicated that five compounds of JOEI interact with five pivotal targets (LDLR, FABP4, ABCB1, PTGS2, and SDC4) that might be strongly correlated with the JOEI-mediated treatment of NSCLC.


The expression level analysis demonstrated that NSCLC tissues exhibit low expression of FABP4, ABCB1, LDLR and PTGS2 and high SDC4 expression. According to the correlation analysis, a decrease in FABP4 expression was strongly correlated with decreases in LDLR and ABCB1, and a decrease in LDLR was strongly correlated with decreased PTGS2 and increased in SDC4 expression. Cox and survival analyses showed that the survival rate of the high-risk group was significantly lower than that of the low-risk group (p = 0.00388). In the survival analysis, the area under the curve (AUC) showed that the pivotal gene model exhibited the best predictive capacity over 4 years (AUC = 0.613). Moreover, the molecular docking analysis indicated that LDLR, FABP4, ABCB1, PTGS2 and SDC4 exhibit good binding activity with the corresponding compounds.


In conclusion, this study predicted and verified that the mechanism of JOEI against NSCLC involves multiple targets and signaling pathways. Furthermore, this study provides candidate targets for the treatment of NSCLC, lays a good foundation for further experimental research and promotes the reasonable application of JOEI in clinical treatment.

Peer Review reports


Based on global estimates, 18.1 million new cancer cases and 9.6 million deaths occurred in 2018. As one of the most common cancers globally, lung cancer remains a critical cause of cancer-related death [1, 2]. Among smokers and nonsmokers, non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer [3]. Due to the limitation of its early detection, the majority of patients with NSCLC are diagnosed at late stages, and the 5-year overall survival (OS) rate is only 11% [4,5,6].. Therefore, an in-depth understanding of the regulatory mechanism of NSCLC occurrence and development is urgently needed to provide more effective strategies for the treatment of this type of cancer.

Traditional Chinese medicine (TCM), as a crucial component of complementary and alternative medical systems, has been widely applied in Asian nations, particularly China, Japan and North and South Korea, for thousands of years for the clinical treatment of cancers [7, 8]. In particular, herbal medicine is considered part of the anticancer strategy in China. A large number of cancer patients prefer to receive TCM via either injection or oral administration when receiving radiotherapy or chemotherapy, [9, 10].

With the continuous expansion of clinical practice toward the comprehensive treatment of tumors, TCM has been proven to be effective in not only relieving adverse events such as fatigue, pain, emesis, diarrhea, and pancytopenia caused by surgery and chemotherapy but also improving quality of life and immune functions and strengthening survival benefits [8, 11,12,13,14].

Javanica oil emulsion injection (JOEI), which is a product produced from Brucea oleifera ether extracts as a raw material, has been engaged as an adjunctive therapy for lung carcinoma, brain metastasis of lung carcinoma, and gastrointestinal tumorigenesis in China [15,16,17,18,19]. Recent studies have recognized that some components of JOEI exhibit specific affinity for tumor cell membranes and potent antitumour activity [20]. Previous investigations have indicated that JOEI can enhance efficacy, improve quality of life and decrease the incidence of platinum-containing chemotherapeutic side effects, such as nausea, vomiting and leukopenia, for patients with advanced NSCLC in the clinic, but no relevant study has attempted to explain its mechanism [16, 21]. To enhance the treatment effect of JOEI, the molecular and biological basis of JOEI in the treatment of NSCLC needs to be elucidated [22].

Network pharmacology has recently emerged as a novel strategy for identifying the bioactive compounds of several TCM formulas and their underlying complex pharmacological mechanisms from systemic and holistic perspectives [12, 23,24,25,26,27]. Network pharmacology has been applied to delineate the convoluted interactions among genes, proteins and metabolites related to diseases and drugs from the perspective of networks, which is in line with the multicomponent and multitarget nature of TCM. The integration of network pharmacology and TCM alters the conventional “one target, one drug” paradigm to a “multi-target, multi-component drug” strategy [28].

Therefore, in this study, we employed network pharmacology and bioinformatics methods to investigate and predict the molecular mechanisms underlying the effectiveness of JOEI against NSCLC. A flowchart of the technical strategy used in this study is presented in Fig. 1.

Fig. 1

Flowchart of the technical strategy


Active components and putative targets of JOEI

By a thorough literature review, we aimed to identify and extract the chemical composition of JOEI [8, 10, 11]. All the compounds were then inputted into the PubChem database ( [29] to obtain their respective 3D molecular structure files. Because the targets of the compounds without accurate structural information could not be successfully predicted, we decided to exclude these chemicals after removing replicated data. The 3D chemical structure files of all the active compounds were imported into the Search Tool for Interacting Chemicals (STITCH, [30, 31], SuperPred ( [32], and SwissTargetPrediction ( [33]. To obtain the corresponding known or predicted targets from the above-mentioned three databases after discarding duplicated data, only human targets were analyzed.

Known targets related to NSCLC

The human targets affiliated with NSCLC can be obtained from four resources:

(1) The Therapeutic Target Database (TTD, is a database that furnishes information on acknowledged and explored therapeutic proteins and targeted diseases, nucleic acid targets and pathways as well as the corresponding drugs directed at each of these targets [34]. We screened the TTD using the keyword “non-small cell lung cancer” and acquired 54 known NSCLC-related targets.

(2) DisGeNET is a discovery platform that integrates information from various data sources. DisGeNET provides information on diseases, gene-disease associations, clinical or abnormal human phenotypes, disorders, variant-disease associations, and traits, among other data, to support studies on the mechanisms underlying human diseases [35].

(3) The Gene Expression Omnibus (GEO, is an international overt repository that archives and freely distributes high-throughput gene expression and other functional genomics datasets [36]. Datasets that met the following criteria were potentially included: 1) tissue samples collected from human NSCLC and corresponding adjacent or normal tissues and 2) 30 samples at any rate. For assaying decontrolled gene expression, the differentially expressed genes (DEGs) were identified using the “limma” package of R software [37], and the DEGs in each microarray were also filtered using the same package. Target integration of the DEGs discriminated from four datasets (GSE19804, GSE18842, GSE43458, and GSE62113) was performed using RobustRankAggreg [38]. Genes with a log2-fold change |log2FC| ≥1 and an FDR-adjusted P value < 0.05 were considered DEGs [39].

(4) The Cancer Genome Atlas (TCGA) provides over 2.5 petabytes of genomic, epigenomic, transcriptomic, and proteomic data, and our ability to diagnose, treat, and prevent cancer has benefited from these data [40]. We obtained the NSCLC-related database from, clicked on “gene expression RNAseq”, selected “HTSeq - Counts (n=585) GDC Hub”, clicked on “phenotype” and chose “Phenotype (n=877) GDC Hub”, and the resulting database was analyzed using the ‘edgeR’ package in R [41].

Protein-protein interaction (PPI) analysis

We inputted the NSCLC-related targets and putative targets of certain chemical components into the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, database [42], which is a database of known and predicted PPIs that includes both direct and indirect interactions among proteins. After restricting the species to “Homo sapiens”, PPI data with confidence scores above 0.7 (low: < 0.4; medium: 0.4 to 0.7; and high: > 0.7) were identified as putative targets for further research.

Network construction

The network visualization tool Cytoscape 3.6.1 (, ver. 3.5.1) was adopted to obtain the PPI network map [43]. Common targets between the compound-putative target network and the NSCLC target PPI network were identified as potential targets for the components of JOEI in NSCLC. In such a network, an injection, a compound, or a gene/protein serves as an “edge” and reflects an association between nodes. For each node in the interaction network, three indices (significant parameters) were measured to assess its topological features: degree, betweenness, and closeness. The measure “degree” is construed as the number of edges associated with node i, and nodes with a higher degree are considered more important. The metric “betweenness” represents the number of shortest paths between node pairs passing through node i, and the measure “closeness” is the reciprocal of the sum of the distances from node i to other nodes. Nodes with higher values of these measures are more important in the network. The key hubs in the network all exhibit high centrality [44,45,46,47].

Expression level and correlation analyses of the key targets

The results from the expression level and correlation analyses were visualized through Gene Expression Profiling Interactive Analysis (GEPIA) (, a web-based tool that analyzes tumor data from TCGA and the Genotype-Tissue Expression (GTEx) project. GEPIA contains 9736 tumor samples and 8587 normal tissue samples covering 33 malignancies. The expression analysis between tumor and normal data was performed using a standard processing pipeline [48], which allows both an analysis according to specific conditions, similar to tumor and normal differential expression analysis, and the detection of the expression of the hub targets in NSCLC and normal tissues. A boxplot was then generated to visualize the relationships [49].

Enrichment analysis

To clarify the roles of the potential targets in gene function and signaling pathways, Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the targets in the compound-NSCLC target network were performed using the g:Profiler ( database. The GO project divided functions into three facets, cellular component, molecular function and biological process, and reveals possible biological processes associated with key targets [50, 51]. In addition to pathway enrichment analysis, KEGG pathway enrichment analysis provides pathway functional annotations of a specific gene set. According to the results from the g:Profiler database, the multi-component, multi-target and multi-pathway characteristics of JOEI for treating NSCLC can be illustrated by analyzing the vital GO terms and pathways of the key targets. The results from the GO and KEGG analyses were visualized using the ‘GOplot’ package in R software [52].

Cox and survival analyses

The risk score (RS) was based on the linear combination of the candidate mRNAs for each patient with NSCLC and calculated by multiplying the sum of the mRNA expression values by the single variable Cox regression coefficient [39].

The prediction performance of the model was measured based on the area under the curve (AUC) obtained from the time-dependent receiver operating characteristic (ROC) analysis, and the accuracy of the RS to predict OS at 1 to 5 years was assessed. The capacity of the evaluation model can be obtained by analyzing the AUC of the ROC curve. A larger AUC usually represents better performance, and the AUC was greater than 0.7, which indicated that the model has better classification capacity. All statistical analyses were performed using R software (version 3.4.2), and survival and ROC curves were drawn using the ‘survival’ and ‘survivalROC’ packages, respectively [53, 54].

Molecular docking

Molecular docking has been extensively used for ligand-based and structured-based target prediction. The 3D crystal structures of the candidate targets from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank ( [55] were downloaded to assess these targets. If the root mean square deviation (RMSD) of a model is less than 3 Å, it can be regarded as a decent or precise model (accurate ≤2 Å, reliable ≤4 Å) [56]. The protein structures were prepared using AutoDockTools (ADT) [57], and this analysis includes removing ligand and water molecules, computing Gasteiger charges, adding polar hydrogens, and merging nonpolar hydrogens. The results were then saved in MOL2 format. The compounds were also prepared using ADT, and a Gasteiger charge was assigned to the compounds. The prepared protein structures and compounds were saved in PDBQT format. Molecular docking was then performed with AutoDock Vina, and the results were viewed and analyzed using PyMOL ( [58].


Compound-putative target network

Large-scale text mining identified a total of seven active components in JOEI. After the initial analysis, five active compounds with structural information and 87 putative targets were selected for further study. Detailed information of the five compounds in JOEI is described in Table 1. The compound-putative target network (shown in Fig. 2) was constructed with 92 nodes (five compound nodes and 87 putative target nodes) and 160 edges. In this network, many putative targets were associated with multiple compounds (to trigger their biological effects and vice versa); therefore, the targets that play a pivotal role in the whole network might be considered key compounds or targets. The network pharmacology analysis of all the compounds revealed that the compounds with the highest degrees were linoleic acid and palmitic acid, followed by stearic acid, α-linolenic acid and oleic acid.

Table 1 Information on the chemical components of JOEI
Fig. 2

Compound-putative target network of JOEI

Note: The blue diamonds represent compounds contained in JOEI. The yellow ellipses represent the corresponding targets. The node size has a direct proportional (positive) relationship with the degree.

PPI network of NSCLC targets

A total of 406 NSCLC targets were retrieved from the TTD, DisGeNET, TCGA and GEO databases. As shown in Fig. 3, the PPI network of NSCLC targets depicts the interactions between the 292 target proteins ultimately identified from the STRING database. The major nodes were identified by calculating three topological features for each node in the network.

Fig. 3

PPI network related to NSCLC. Note: The red ellipses represent targets obtained from the TTD. The pink ellipses represent targets obtained from TCGA-down, GEO and TTD. The blue ellipses represent targets obtained from the TTD and DisGeNET. The green ellipses represent targets obtained from TCGA-down and GEO. The yellow ellipses represent targets obtained from TCGA-up and GEO. The orange ellipses represent targets obtained from TCGA-up, TTD, DisGeNET and GEO. The node size has a direct proportional (positive) relationship with the degree

Note: The red ellipses represent targets obtained from the TTD. The pink ellipses represent targets obtained from TCGA-down, GEO and TTD. The blue ellipses represent targets obtained from the TTD and DisGeNET. The green ellipses represent targets obtained from TCGA-down and GEO. The yellow ellipses represent targets obtained from TCGA-up and GEO. The orange ellipses represent targets obtained from TCGA-up, TTD, DisGeNET and GEO. The node size has a direct proportional (positive) relationship with the degree.

Identification of core genes and network analysis

To further unveil the therapeutic mechanism of JOEI resistance in NSCLC, the overlapping genes between compound and NSCLC targets were identified. We found five genes in both the list of NSCLC targets and the list of putative targets (Table 2). As displayed in Fig. 4, the compound-NSCLC target network involved 10 nodes (five common targets and five corresponding chemical components) and 11 edges, which indicated that the 10 nodes might act as potential targets for the treatment of NSCLC with JOEI.

Table 2 Compound-NSCLC target network
Fig. 4

Compound-NSCLC target network. Note: The red hexagons represent compounds of JOEI, and the blue circles represent potential targets of JOEI against NSCLC

Expression level and correlation analyses of the key targets

The prognostic information for the five key genes is available for free in the GEPIA database.

We subsequently employed GEPIA to examine the differences in hub gene expression between NSCLC and normal tissues, as shown in Fig. 5.

Fig. 5

Gene expression level analysis of 5 hub genes in human NSCLC. Note: Red and gray boxes represent normal and cancer tissues, respectively

Fatty acid-binding protein 4 (FABP4), ATP-binding cassette subfamily B member 1 (ABCB1), low-density lipoprotein receptor (LDLR) and prostaglandin endoperoxide synthase 2 (PTGS2/COX-2) are highly expressed in NSCLC tissues, and the expression of syndecan 4 (SCD4) in these tissues was low (Fig. 5). A decrease in FABP4 expression was strongly correlated with decreases in LDLR and ABCB1, and a decrease in LDLR was strongly correlated with decreased PTGS2 and increased in SDC4 expression (Fig. 6).

Fig. 6

Correlation analysis of five hub genes in human NSCLC

GO and KEGG pathway enrichment analyses

To further explore the multiple mechanisms of JOEI in NSCLC at the system level, we performed a GO enrichment analysis of five targets in the compound-NSCLC target network and identified five enriched GO terms (FDR < 0.01 and P < 0.01, as shown in Fig. 7a). Regarding biological processes, the potential targets were enriched in regulation of the response to osmotic stress (GO:0047484), positive regulation of the inflammatory response (GO:0050729), response to lithium ion (GO:0010226) and brown fat cell differentiation (GO:0050873). The analysis of molecular functions revealed that ceramide-translocating ATPase activity (GO:0099038) was particularly enriched.

Fig. 7

GO (a) and KEGG pathway (b) analyses of key targets

To elucidate the crucial pathways among the five potential targets in NSCLC treatment, we identified three pathways based on the criteria FDR < 0.01 and P < 0.01 (as shown in Figs. 7b, 8 and 9): ovarian steroidogenesis (KEGG:04913), regulation of lipolysis in adipocytes (KEGG:04923) and bile secretion (KEGG:04976). Figure 10 shows the interactions between chemical components in JOEI and predictive targets and pathways of JOEI against NSCLC.

Fig. 8

Graph of the interaction pathway

Fig. 9

Signaling pathways

Fig. 10

Compound-target-pathway network. Note: The red octagons represent JOEI; the five orange diamonds represent the chemical components of JOEI; the 97 purple hexagons represent the prediction targets; the common targets of JOEI and NSCLC are marked with yellow; and three green triangles represent the critical paths of the targets

Cox and survival analyses

The crucial genes were identified from the NSCLC cohort in TCGA. In both the high-risk group and the low-risk group, FABP4 and ABCB1 were weakly expressed, and SDC4, LDLR and PTGS2 were highly expressed (Fig. 11). The survival analysis showed that the survival rate of the high-risk group was fairly lower than that of the low-risk group (p = 0.00388). The AUC obtained from the survival analysis demonstrated that the crucial gene model exhibited the best predictive capacity over 4 years (AUC = 0.613) (Fig. 11).

Fig. 11

Heatmap of the five targets in patients in the low- and high-risk groups and prognostic validation of the core targets in the NSCLC cohort

Molecular docking simulation

The mechanism of JOEI in the treatment of NSCLC was elucidated by investigating the interactions between compounds and targets. Therefore, the interactions between four compounds of JOEI (linoleic acid, oleic acid, palmitic acid, and stearic acid) and five targets (FABP4, ABCB1, LDLR, PTGS2 and SDC4) were investigated through molecular docking simulations. The 3D crystal structures of the five targets were derived from the PDB database based on their respective PDB codes. The results showed that four compounds exhibited relatively high potential for binding to the active sites of the five targets (Table 3). As shown in Fig. 12, hydrogen bond interactions were found between four compounds of JOEI and five targets.

Table 3 Docking information of five targets with their corresponding compounds
Fig. 12

Detailed target-compound interactions obtained from the docking simulation


Based on histological characteristics, lung cancer can be divided into small cell lung cancer and NSCLC, and NSCLC accounts for 85% of all lung cancer cases [4, 59,60,61]. Despite great advances in the treatment of lung cancer, the OS rate of patients with NSCLC remains low [62]. As one of the crucial options for comprehensive cancer treatment, TCM has long been used to comprehensively treat NSCLC due to particular advantages, such as improving survival benefits, inhibiting tumor growth, and relieving postoperative symptoms and complications [63].

Explaining the mechanisms through which TCMs, as a multi-component, multi-target, and multi-pathway therapy, achieves its special therapeutic effect on the biological network of body systems is difficult [64, 65]. Favorably, network pharmacology presents a new perspective for cooperating with a new realization of the mechanisms of drugs and has become an dynamic method that incorporating systems biology, bioinformatics, and polypharmacology [22, 23, 66]. This approach updates the “one target, one drug” model to the “multi-component and multi-target” model, better elucidates the complex interactions among genes, proteins and metabolites during the drug treatment of diseases from a network perspective and provides evidence at the molecular biology level [67,68,69].

In this study, we implemented network pharmacology to identify bioactive components and targets of JOEI with the aim of identifying common targets in NSCLC and understanding and evaluating the underlying mechanism of JOEI in the treatment of NSCLC through expression level, correlation, enrichment, Cox, survival and molecular docking analyses.

According to the compound-NSCLC target network, five nodes are likely to be the core targets in NSCLC treatment. A previous study demonstrated that the FABP4 levels ae higher in NSCLC tissues than in normal tissues and that these high FABP4 levels have an unfavorable impact on the OS of NSCLC patients. Thus, the detection of FABP4 is helpful for predicting the prognosis of patients with NSCLC [70]. ABCB1 reportedly plays an important role in overcoming ABCB1-mediated docetaxel resistance in lung cancer [71]. Another study observed that ABCB1 is highly expressed in patients with stage I lung adenocarcinoma and that the expression of this protein is associated with poor survival, which indicates that ABCB1 expression is useful for predicting the prognosis of patients with lung adenocarcinoma [72]. Yang et al. identified ABCB1 as a vital downstream target of the chromosomal helicase/ATPase DNA-binding protein 1-like gene in NSCLC cells. The knockout of ABCB1 and ectopic expression of the chromosomal helicase/ATPase DNA-binding protein 1-like gene enhanced the effect of cisplatin on NSCLC cell apoptosis [73]. Regarding LDLR, Yang et al. demonstrated that T lymphocytes (LMPs) exert antiangiogenic and proapoptotic effects that lead to inhibition of lung carcinoma by decreasing the vascular endothelial growth factor levels, and the knockdown of LDLR reduces the uptake of LMPs by Lewis lung carcinoma cells and attenuates the inhibitory effects of LMPs on cell growth and vascular endothelial growth factor expression. These results show that LMPs portray a new treatment protocol for treating lung carcinomas and indicate that LDLR plays an important role [74]. With respect to PTGS2/COX-2, Jiang et al. indicated that PTGS2/COX-2 might promote cisplatin resistance in NSCLC by favoring epithelial-mesenchymal transition through activation of the AKT signaling pathway [75]. Previous studies have shown that the inhibition of PTGS2 might play a beneficial role in the treatment of NSCLC, such as improving the overall response rate of advanced NSCLC and suppressing the metastasis of lung cancer cells [76,77,78,79]. Some data suggest that PTGS2 is likely a potential prognostic marker for unresectable NSCLC [80]. Concerning SCD4, high Toll-like receptor 7 expression is associated with the overexpression of SDC4 in patients with adenocarcinoma, which suggests that its expression is related to metastasis. SDC4 also plays a role in the occurrence and metastasis of renal cell carcinoma [49, 81, 82]. Repressor of silencing 1 (ROS1) protein-tyrosine kinase fusion proteins are expressed in 1–2% of NSCLC patients [83]. For NSCLC patients with tumors expressing the ROS1 fusion gene, ROS1 inhibition might be an effective treatment protocol, and SDC4 plays a vital role as a common ROS1 fusion partner [84, 85].

The compound-putative target network included linoleic acid, α-linolenic acid, palmitic acid, stearic acid and oleic acid. We found that linoleic acid induces the expression of PTGS2 in retinal pigment epithelial cells at the mRNA and protein levels in a time- and dose-dependent manner [86]. PTGS2 expression is a powerful predictor of NSCLC [87]. In NSCLC, an allele of chromosome 3p is often lost, which confirms the existence of cancer suppressor genes in this chromosomal region. We found that a Fus1 peptide inhibits ABL tyrosine kinase in vitro. The repressive Fus1 sequence stems from a deleted region of the mutant Fus1 gene detected in lung cancer cell lines, and notably, a stearic acid-modified form of this peptide is required for inhibition [88]. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are effective in the treatment of NSCLC patients with EGF mutations, but resistance is inevitable. The cytotoxic effect of both gefitinib and osimertinib in EGFR-activated mutant cell lines can be inhibited by oleic acid [89]. The FABP4 inhibitor inhibited cell growth induced by oleic acid, leptin, vascular endothelial growth factor, and DHA (P < 0.05). The levels of FABP4 protein in these cells are increased by oleic acid vascular endothelial cells and leptin [90]. An increase in the miR-146b-5p level is related to decreased FABP4 expression, glucose metabolism and FABP4 mobilization. In partial agreement with these findings, palmitic acid lead to decreased miR-146a levels in vitro; thus, FABP4 is associated with palmitic acid [91], which is consistent with the results of our study.

In this study, we performed enrichment analyses to clarify the multiple mechanisms of JOEI in the treatment of NSCLC at the system level. We found that the pathways directly related to lung cancer were ovarian steroidogenesis, regulation of lipolysis in adipocytes and bile secretion. The production of ovarian steroidogenesis is vital for the normal function of the uterus, the establishment and maintenance of pregnancy and the development of the mammary gland; it also demands cooperative interactions between the theca and granulosa cells within the follicle [92]. Morphological examinations play important roles in the assessment of ovarian steroidogenesis, particularly in patients with ovarian tumors associated with abnormal sexual steroids [93]. Increased lipogenesis is one of the most important metabolic characteristics of cancer cells. Recent findings have revealed that breast and liposarcoma cancers have both de novo fatty acid synthesis pathways and lipoprotein lipase-mediated extracellular lipolysis. Nonetheless, recent studies have shown that the proliferation and survival of cancer cells are affected by fatty acids, and some cancer cells/tissues can obtain fatty acids through adipogenesis and lipolysis [94,95,96]. Bile normally functions to emulsify and facilitate the intestinal absorption of dietary fats, protect the organism from enteric infections by excreting immune globulin A and inflammatory cytokines, and stimulate the innate immune system in the intestine. Bile secretion plays a vital role in the health of an organism, and therefore, disrupted bile secretion can eventually result in liver failure or death [97].


In conclusion, the current study explored and predicted the molecular mechanism of JOEI against NSCLC using a network pharmacology and bioinformatics approach. We hope that our study will lay a good foundation for further experimental studies and contribute to the application of network pharmacology for exploring the potential mechanisms of complex diseases. However, because this study was based on data analysis, further experimental data from in vitro and in vivo experiments are needed to verify the findings and optimize the method.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.





Area under the curve


Differentially expressed genes


The gene expression omnibus


Gene expression profiling interactive analysis


Genotype-tissue expression


Gene ontology


Javanica oil emulsion injection


Kyoto encyclopedia of genes and genomes


Non-small cell lung cancer


Overall survival


Traditional Chinese medicine


Therapeutic target database


Research Collaboratory for Structural Bioinformatics


Root mean square deviation


Receiver operating characteristic


Risk score


  1. 1.

    Tang X, Yang Y, Song X, Liu X, Wang X, Huang F, Li Y, Chen F, Wan H. SIX4 acts as a master regulator of oncogenes that promotes tumorigenesis in non-small-cell lung cancer cells. Biochem Biophys Res Commun. 2019;516(3):851–7.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article  Google Scholar 

  3. 3.

    Mortezaei Z, Tavallaei M, Hosseini SM. Considering smoking status, coexpression network analysis of non-small cell lung cancer at different cancer stages, exhibits important genes and pathways. J Cell Biochem. 2019;120(11):19172–85.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Li Z, Feng C, Guo J, Hu X, Xie D. GNAS-AS1/miR-4319/NECAB3 axis promotes migration and invasion of non-small cell lung cancer cells by altering macrophage polarization. Funct Integr Genomics. 2019.

  5. 5.

    Kogita A, Togashi Y, Hayashi H, Sogabe S, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition. Int J Oncol. 2014;45(4):1430–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8(9):784–96.

    PubMed  Article  Google Scholar 

  7. 7.

    Yao Y, Zhang X, Wang Z, Zheng C, Li P, Huang C, Tao W, Xiao W, Wang Y, Huang L, Yang L. Deciphering the combination principles of traditional Chinese medicine from a systems pharmacology perspective based on Ma-huang decoction. J Ethnopharmacol. 2013;150(2):619–38.

    PubMed  Article  Google Scholar 

  8. 8.

    Chen R, He J, Tong X, Tang L, Liu M. The Hedyotis diffusa Willd. (Rubiaceae): A Review on Phytochemistry, Pharmacology, Quality Control and Pharmacokinetics. Molecules. 2016;21(6):710.

    PubMed Central  Article  CAS  Google Scholar 

  9. 9.

    Wang J, Ye HB, Dong Y. Effects of javanica oil emulsion injection combined with radiotherapy versus radiotherapy alone on the efficacy and safety in patients with esophageal cancer: a pooled analysis of 1269 cases. J BUON. 2017;22(4):985–95.

    CAS  PubMed  Google Scholar 

  10. 10.

    Liu J, Li X, Liu J, Ma L, Li X, Fønnebø V. Traditional Chinese medicine in cancer care: a review of case reports published in Chinese literature. Forsch Komplementmed. 2011;18(5):257–63.

    PubMed  Article  Google Scholar 

  11. 11.

    Chen Y, Lin Y, Li Y, Li C. Total flavonoids of Hedyotis diffusa Willd inhibit inflammatory responses in LPS-activated macrophages via suppression of the NF-κB and MAPK signaling pathways. Exp Ther Med. 2016;11(3):1116–22.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Ahmad R, Ali AM, Israf DA, Ismail NH, Shaari K, Lajis NH. Antioxidant, radical-scavenging, anti-inflammatory, cytotoxic and antibacterial activities of methanolic extracts of some Hedyotis species. Life Sci. 2005;76(17):1953–64.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Lin CC, Ng LT, Yang JJ, Hsu YF. Anti-inflammatory and hepatoprotective activity of peh-hue-juwa-chi-cao in male rats. Am J Chin Med. 2002;30(2–3):225–34.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Wang JC, Tian JH, Ge L, Gan YH, Yang KH. Which is the best Chinese herb injection based on the FOLFOX regimen for gastric cancer? A network meta- analysis of randomized controlled trials. Asian Pac J Cancer Prev. 2014;15(12):4795–800.

    PubMed  Article  Google Scholar 

  15. 15.

    Wu JR, Liu SY, Zhu JL, Zhang D, Wang KH. Efficacy of Brucea javanica oil emulsion injection combined with the chemotherapy for treating gastric Cancer: a systematic review and Meta-analysis. Evid Based Complement Alternat Med. 2018.

  16. 16.

    Xu W, Jiang X, Xu Z, Ye T, Shi Q. The efficacy of Brucea javanica oil emulsion injection as adjunctive therapy for advanced non-small-cell lung Cancer: a Meta-analysis. Evid Based Complement Alternat Med. 2016.

  17. 17.

    Ji ZQ, Huang XE, Wu XY, Liu J, Wang L, Tang JH. Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev. 2014;15(20):8603–5.

    PubMed  Article  Google Scholar 

  18. 18.

    Majid MZ, Zaini ZM, Razak FA. Apoptosis-inducing effect of three medicinal plants on oral cancer cells KB and ORL-48. ScientificWorldJournal. 2014.

  19. 19.

    Lu YY, Huang XE, Cao J, Xu X, Wu XY, Liu J, Xiang J, Xu L. Phase II study on Javanica oil emulsion injection (Yadanzi®) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Asian Pac J Cancer Prev. 2013;14(8):4791–4.

    PubMed  Article  Google Scholar 

  20. 20.

    Yang F, Yu XH, Qiao F, Cheng LH, Chen G, Long X, Wang XR, Li XL, Liang RC, Chen YZ. Formulation and characterization of Brucea javanica oil microemulsion for improving safety. Drug Dev Ind Pharm. 2014;40(2):266–77.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Wang Q, Wang M, He X, Gao T, Cao H, Dou W, Tian J. Meta-analysis on treatment of non-small cell lung cancer with brucea javanica oil emulsion in combination with platinum-contained first-line chemotherapy. Zhongguo Zhong Yao Za Zhi. 2012;37(13):2022–9.

    PubMed  Google Scholar 

  22. 22.

    Liu L, Du B, Zhang H, Guo X, Zhou Z, Xiu A, Liu C, Su S, Ai H. A network pharmacology approach to explore the mechanisms of Erxian decoction in polycystic ovary syndrome. Chin Med. 2018;13(46):1–12.

  23. 23.

    Wang S, Tong Y, Ng TB, Lao L, Lam JK, Zhang KY, Zhang ZJ, Sze SC. Network pharmacological identification of active compounds and potential actions of Erxian decoction in alleviating menopause-related symptoms. Chin Med. 2015;10(19):1–12.

  24. 24.

    Wu L, Wang Y, Li Z, Zhang B, Cheng Y, Fan X. Identifying roles of “Jun-Chen-Zuo-Shi” component herbs of QiShenYiQi formula in treating acute myocardial ischemia by network pharmacology. Chin Med. 2014;9(24):1–9.

  25. 25.

    Lee S. Systems biology - a pivotal research methodology for understanding the mechanisms of traditional medicine. Aust J Pharm. 2015;18(3):11–8.

    Google Scholar 

  26. 26.

    Zhang GB, Li QY, Chen QL, Su SB. Network pharmacology: a new approach for chinese herbal medicine research. Evid Based Complement Alternat Med. 2013;2013:621423.

    PubMed  PubMed Central  Google Scholar 

  27. 27.

    Hao DC, Xiao PG. Network pharmacology: a Rosetta stone for traditional Chinese medicine. Drug Dev Res. 2014;75(5):299–312.

    CAS  Article  Google Scholar 

  28. 28.

    Li S. Exploring traditional chinese medicine by a novel therapeutic concept of network target. Chin J Integr Med. 2016;22(9):647–52.

    PubMed  Article  Google Scholar 

  29. 29.

    Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, Han L, He J, He S, Shoemaker BA, Wang J, Yu B, Zhang J, Bryant SH. PubChem substance and compound databases. Nucleic Acids Res. 2016;44(D1):D1202–13.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2016;44(D1):D380–4.

    CAS  PubMed  Article  Google Scholar 

  31. 31.

    Hong M, Li S, Tan HY, Cheung F, Wang N, Huang J, Feng Y. A network-based pharmacology study of the herb-induced liver injury potential of traditional Hepatoprotective Chinese herbal medicines. Molecules. 2017;22(4):632.

    PubMed Central  Article  CAS  Google Scholar 

  32. 32.

    Nickel J, Gohlke BO, Erehman J, Banerjee P, Rong WW, Goede A, Dunkel M, Preissner R. SuperPred: update on drug classification and target prediction. Nucleic Acids Res. 2014;42(W1):W26–31.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res. 2014;42(W1):W32–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Tang H, He S, Zhang X, Luo S, Zhang B, Duan X, Zhang Z, Wang W, Wang Y, Sun Y. A network pharmacology approach to uncover the pharmacological mechanism of XuanHuSuo powder on osteoarthritis. Evid Based Complement Alternat Med. 2016;2016:3246946.

    PubMed  PubMed Central  Google Scholar 

  35. 35.

    Piñero J, Queralt-Rosinach N, Bravo À, Deu-Pons J, Bauer-Mehren A, Baron M, Sanz F, Furlong LI. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. Database (Oxford). 2015;2015:bav028.

    Article  CAS  Google Scholar 

  36. 36.

    Clough E, Barrett T. The gene expression omnibus database. Methods Mol Biol. 2016;1418:93–110.

    PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Limma powers differential expression analyses for rna-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  38. 38.

    Yo YT, Shieh GS, Hsu KF, Wu CL, Shiau AL. Licorice and licochalcone-a induce autophagy in LNCaP prostate cancer cells by suppression of Bcl-2 expression and the mTOR pathway. J Agric Food Chem. 2009;57(18):8266–73.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Bing Z, Cheng Z, Shi D, Liu X, Tian J, Yao X, Zhang J, Wang Y, Yang K. Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology. BMC Complement Altern Med. 2018;18(1):293.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Sanga S, Vladimirova A, Goold RD, Klingler TM. Abstract 4870: GenePool: a cloud-based technology for rapidly data mining large-scale, patient-derived cancer genomic cohorts including the Cancer genome atlas. Cancer Res. 2015;75:4870.

    Google Scholar 

  41. 41.

    Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–40.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–8.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol. 2011;696:291–303.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Liu H, Zeng L, Yang K, Zhang G. A network pharmacology approach to explore the pharmacological mechanism of Xiaoyao powder on Anovulatory infertility. Evid Based Complement Alternat Med. 2016;2016:2960372.

    PubMed  PubMed Central  Google Scholar 

  45. 45.

    Jeong H, Mason SP, Barabási AL, Oltvai ZN. Lethality and centrality in protein networks. Nature. 2001;411:41–2.

    CAS  PubMed  Article  Google Scholar 

  46. 46.

    Newman MEJ. A measure of betweenness centrality based on random walks. Soc Networks. 2005;27(1):39–54.

    Article  Google Scholar 

  47. 47.

    Sabidussi G. The centrality index of a graph. Psychometrika. 1966;31(4):581–603.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Sun M, Song H, Wang S, Zhang C, Zheng L, Chen F, Shi D, Chen Y, Yang C, Xiang Z, Liu Q, Wei C, Xiong B. Integrated analysis identifies microRNA-195 as a suppressor of hippo-YAP pathway in colorectal cancer. J Hematol Oncol. 2017;10(1):79.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  50. 50.

    Gene Ontology Consortium. Creating the gene ontology resource: design and implementation. Genome Res. 2001;11(8):1425–33.

    Article  Google Scholar 

  51. 51.

    Wixon J, Kell D. The Kyoto encyclopedia of genes and genomes—KEGG. Yeast. 2000;17(1):48–55.

    CAS  PubMed  Google Scholar 

  52. 52.

    Walter W, Sánchez-Cabo F, Ricote M. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. 2015;31(17):2912–4.

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Kassambara A, Kosinski M, Biecek P. Survminer: drawing survival curves using ‘ggplot2’; 2016.

    Google Scholar 

  54. 54.

    Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–44.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Liu H, Wang L, Lv M, Pei R, Li P, Pei Z, Wang Y, Su W, Xie XQ. AlzPlatform: an Alzheimer's disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research. J Chem Inf Model. 2014;54(4):1050–60.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Rayan A. New tips for structure prediction by comparative modeling. Bioinformation. 2009;3(6):263–7.

    PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–91.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Leung AW, de Silva T, Bally MB, Lockwood WW. Synthetic lethality in lung cancer and translation to clinical therapies. Mol Cancer. 2016;15(1):61.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  60. 60.

    Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 2012;62(5):283–98.

    PubMed  Article  Google Scholar 

  61. 61.

    Team NLSTR, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JD, Jain A, Baum S. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980–91.

    Article  CAS  Google Scholar 

  62. 62.

    Tu SH, Ho CT, Liu MF, Huang CS, Chang HW, Chang CH, Wu CH, Ho YS. Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression. Food Chem. 2013;141(2):1553–61.

    CAS  PubMed  Article  Google Scholar 

  63. 63.

    Xu W, Yang G, Xu Y, Zhang Q, Fu Q, Yu J, Yu M, Zhao W, Yang Z, Hu F, Han D, Wang X. The possibility of traditional chinese medicine as maintenance therapy for advanced nonsmall cell lung cancer. Evid Based Complement Alternat Med. 2014;2014:278917.

    PubMed  PubMed Central  Google Scholar 

  64. 64.

    Zhang YX, Cheng XR, Zhou WX. Drug repositioning-the important field of network pharmacology. Chin J Pharm Toxicol. 2012;26(6):779–86.

    Google Scholar 

  65. 65.

    Wang J, Li XJ. Network pharmacology and drug discovery. Prog Physiol Sci. 2011;42(4):241–5.

    Google Scholar 

  66. 66.

    Liu X, Wu J, Zhang D, Wang K, Duan X, Meng Z, Zhang X. Network Pharmacology-Based Approach to Investigate the Mechanisms of Hedyotis diffusa Willd in the Treatment of Gastric Cancer. Evid Based Complement Alternat Med. 2018;2018:7802639.

    PubMed  PubMed Central  Google Scholar 

  67. 67.

    Zhang S, Shan L, Li Q, Wang X, Li S, Zhang Y, Fu J, Liu X, Li H, Zhang W. Systematic analysis of the multiple bioactivities of green tea through a network pharmacology approach. Evid Based Complement Alternat Med. 2014;2014:512081.

    PubMed  PubMed Central  Google Scholar 

  68. 68.

    Zhang Y, Mao X, Su J, Geng Y, Guo R, Tang S, Li J, Xiao X, Xu H, Yang H. A network pharmacology-based strategy deciphers the underlying molecular mechanisms of Qixuehe Capsule in the treatment of menstrual disorders. Chin Med. 2017;12(23):1–11.

  69. 69.

    Li T, Baochen Z, Yue Z, Cheng W, Yali W, Zongxi S, Wantong Z, Yang L, Shouying D. Network pharmacology-based identification of pharmacological mechanism of SQFZ injection in combination with Docetaxel on lung cancer. Sci Rep. 2019;9(1):4533.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  70. 70.

    Tang Z, Shen Q, Xie H, Zhou X, Li J, Feng J, Liu H, Wang W, Zhang S, Ni S. Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC). Oncotarget. 2016;7(29):46253–62.

    PubMed  PubMed Central  Article  Google Scholar 

  71. 71.

    Chen H, Shien K, Suzawa K, Tsukuda K, Tomida S, Sato H, Torigoe H, Watanabe M, Namba K, Yamamoto H, Soh J, Asano H, Miyoshi S, Toyooka S. Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer. Oncol Lett. 2017;14(4):4349–54.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  72. 72.

    Zou F, Seike M, Noro R, Kunugi S, Kubota K, Gemma A. Prognostic significance of ABCB1 in stage I lung adenocarcinoma. Oncol Lett. 2017;14(1):313–21.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  73. 73.

    Li Y, He LR, Gao Y, Zhou NN, Liu Y, Zhou XK, Liu JF, Guan XY, Ma NF, Xie D. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer. Cell Death Dis. 2019;10(2):99.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  74. 74.

    Yang C, Gagnon C, Hou X, Hardy P. Low density lipoprotein receptor mediates anti-VEGF effect of lymphocyte T-derived microparticles in Lewis lung carcinoma cells. Cancer Biol Ther. 2010;10(5):448–56.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  75. 75.

    Jiang GB, Fang HY, Tao DY, Chen XP, Cao FL. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner. Eur Rev Med Pharmacol Sci. 2019;23(9):3838–46.

    PubMed  Google Scholar 

  76. 76.

    Ammu VVVRK, Garikapati KK, Krishnamurthy PT, Chintamaneni PK, Pindiprolu SKSS. Possible role of PPAR-γ and COX-2 receptor modulators in the treatment of non-small cell lung carcinoma. Med Hypotheses. 2019;124:98–100.

    Article  CAS  Google Scholar 

  77. 77.

    Dai P, Li J, Ma XP, Huang J, Meng JJ, Gong P. Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis. Onco Targets Ther. 2018;11:721–30.

    PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    Zhou YY, Hu ZG, Zeng FJ, Han J. Clinical profile of Cyclooxygenase-2 inhibitors in treating non-small cell lung Cancer: a Meta-analysis of nine randomized clinical trials. PLoS One. 2016;11(3):e0151939.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  79. 79.

    Che D, Zhang S, Jing Z, Shang L, Jin S, Liu F, Shen J, Li Y, Hu J, Meng Q, Yu Y. Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE2/β-catenin signalling pathway. Mol Immunol. 2017;90:197–210.

    CAS  PubMed  Article  Google Scholar 

  80. 80.

    Butkiewicz D, Krześniak M, Drosik A, Giglok M, Gdowicz-Kłosok A, Kosarewicz A, Rusin M, Masłyk B, Gawkowska-Suwińska M, Suwiński R. The VEGFR2, COX-2 and MMP-2 polymorphisms are associated with clinical outcome of patients with inoperable non-small cell lung cancer. Int J Cancer. 2015;137(10):2332–42.

    CAS  PubMed  Article  Google Scholar 

  81. 81.

    Dajon M, Iribarren K, Petitprez F, Marmier S, Lupo A, Gillard M, Ouakrim H, Victor N, Vincenzo DB, Joubert PE, Kepp O, Kroemer G, Alifano M, Damotte D, Cremer I. Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells. Oncoimmunology. 2018;8(1):e1505174.

    PubMed  PubMed Central  Article  Google Scholar 

  82. 82.

    Erdem M, Erdem S, Sanli O, Sak H, Kilicaslan I, Sahin F, Telci D. Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma. Urol Oncol. 2014;32(1):25.e13–20.

    CAS  Article  Google Scholar 

  83. 83.

    Jr RR. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacol Res 2017; 121: 202–212.

  84. 84.

    Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18(17):4570–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  85. 85.

    Park S, Ahn BC, Lim SW, Sun JM, Kim HR, Hong MH, Lee SH, Ahn JS, Park K, Choi Y, Cho BC, Ahn MJ. Characteristics and outcome of ROS1-positive non-small cell lung Cancer patients in routine clinical practice. J Thorac Oncol. 2018;13(9):1373–82.

    PubMed  Article  Google Scholar 

  86. 86.

    Fang IM, Yang CH, Yang CM, Chen MS. Linoleic acid-induced expression of inducible nitric oxide synthase and cyclooxygenase II via p42/44 mitogen-activated protein kinase and nuclear factor-kappaB pathway in retinal pigment epithelial cells. Exp Eye Res. 2007;85(5):667–77.

    CAS  PubMed  Article  Google Scholar 

  87. 87.

    Shimizu K, Yukawa T, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy. World J Surg Oncol. 2015;13(21):1–7.

  88. 88.

    Lin J, Sun T, Ji L, Deng W, Roth J, Minna J, Arlinghaus R. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene. 2007;26(49):6989–96.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  89. 89.

    Huang Q, Wang Q, Li D, Wei X, Jia Y, Zhang Z, Ai B, Cao X, Guo T, Liao Y. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):129.

    PubMed  PubMed Central  Article  Google Scholar 

  90. 90.

    Pandya AD, Das MK, Sarkar A, Vilasagaram S, Basak S, Duttaroy AK. Tube formation in the first trimester placental trophoblast cells: differential effects of angiogenic growth factors and fatty acids. Cell Biol Int. 2016;40(6):652–61.

    CAS  PubMed  Article  Google Scholar 

  91. 91.

    Latorre J, Moreno-Navarrete JM, Mercader JM, Sabater M, Rovira Ò, Gironès J, Ricart W, Fernández-Real JM, Ortega FJ. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD. Int J Obes. 2017;41(4):620–30.

    CAS  Article  Google Scholar 

  92. 92.

    Craig ZR, Wang W, Flaws JA. Endocrine-disrupting chemicals in ovarian function: effects on steroidogenesis, metabolism and nuclear receptor signaling. Reproduction. 2011;142(5):633–46.

    CAS  PubMed  Article  Google Scholar 

  93. 93.

    Sasano H. Functional pathology of human ovarian steroidogenesis: Normal cycling ovary and steroid-producing neoplasms. Endocr Pathol. 1994;5(2):81–9.

    PubMed  Article  Google Scholar 

  94. 94.

    Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013;52(4):585–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  95. 95.

    Kuemmerle NB, Rysman E, Lombardo PS, Flanagan AJ, Lipe BC, Wells WA, Pettus JR, Froehlich HM, Memoli VA, Morganelli PM, Swinnen JV, Timmerman LA, Chaychi L, Fricano CJ, Eisenberg BL, Coleman WB, Kinlaw WB. Lipoprotein lipase links dietary fat to solid tumor cell proliferation. Mol Cancer Ther. 2011;10(3):427–36.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  96. 96.

    Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 2010;140(1):49–61.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  97. 97.

    Boyer JL. Bile formation and secretion. Compr Physiol. 2013;3(3):1035–78.

    PubMed  PubMed Central  Google Scholar 

Download references


Not applicable.


This work was supported by the Young Scientists Training Program of Beijing University of Chinese Medicine (No. BUCM-QNLJ 2019001) and the National Nature Science Foundation of China (Grant No. 81473547 and 81673829).

The funder Jiarui Wu is responsible for conceiving and designing the study, writing and revising the manuscript, reviewing the data, and reading and approving the final manuscript.

Author information




NMW, LXK and WJR conceived and designed the study. NMW, JSS, ZJY, GSY, LJL, WHJ, LYY and ZXM collected the data. NMW, MZQ, LSY and ZW performed the data analysis. NMW, LXK and WJR wrote and revised the manuscript. All the authors are responsible for reviewing the data. All the authors read and approved the final manuscript.

Corresponding author

Correspondence to Jiarui Wu.

Ethics declarations

Ethics approval and consent to participate

Ethical approval was not necessary in the current study because our study gathered data only from the TTD, DisGeNET, GEO and TCGA databases, and this procedure did not address any patient’s personal data or harm any patient.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests in any aspect.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ni, M., Liu, X., Meng, Z. et al. A bioinformatics investigation into the pharmacological mechanisms of javanica oil emulsion injection in non-small cell lung cancer based on network pharmacology methodologies. BMC Complement Med Ther 20, 174 (2020).

Download citation


  • Traditional Chinese medicine
  • Javanica oil emulsion injection
  • Non-small cell lung cancer
  • Network pharmacology
  • Molecular docking